A targeted adenovirus vector displaying a human fibronectin type III domain-based monobody in a fiber protein

Biomaterials

Volumn 34, Issue 16, 2013, Pages 4191-4201

  Matsui, Hayato ^a   Sakurai, Fuminori ^a   Katayama, Kazufumi ^a   Abe, Yasuhiro ^b   Machitani, Mitsuhiro ^a   Kurachi, Shinnosuke ^a,b   Tachibana, Masashi ^a   Mizuguchi, Hiroyuki ^a,b  

^a OSAKA UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

Author keywords

Adenovirus vector; EGFR; Knobless fiber; Monobody; Targeted gene delivery; VEGFR2

Indexed keywords

ADENOVIRUS VECTOR; EGFR; MONOBODY; TARGETED GENE DELIVERY; VEGFR-2;

ANTIBODIES; BACTERIOPHAGES; FIBERS; GENE TRANSFER; MOLECULES; SURFACE PLASMON RESONANCE; TISSUE; VECTORS;

SCAFFOLDS (BIOLOGY);

ADENOVIRUS VECTOR; CAPSID PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBRONECTIN; FIBRONECTIN TYPE 3; NANOBODY; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; VIRUS FIBER PROTEIN;

ARTICLE; BACTERIOPHAGE T4; CARBOXY TERMINAL SEQUENCE; CHIMERA; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN STRUCTURE; SURFACE PLASMON RESONANCE; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; ANTIBODIES; BLOTTING, WESTERN; CELL LINE, TUMOR; FIBRONECTINS; GENETIC THERAPY; GENETIC VECTORS; HUMANS; MICE; MUTATION; NIH 3T3 CELLS; PROTEIN STRUCTURE, TERTIARY; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURFACE PLASMON RESONANCE; TRANSDUCTION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VIRAL PROTEINS;

ADENOVIRIDAE; MIRIDAE;

EID: 84874969358     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.02.046     Document Type: Article

References (62)

1. Hogg R.T., Thorpe P., Gerard R.D. Retargeting adenoviral vectors to improve gene transfer into tumors. Cancer Gene Ther 2011, 18:275-287.
2. Duffy M.R., Parker A.L., Bradshaw A.C., Baker A.H. Manipulation of adenovirus interactions with host factors for gene therapy applications. Nanomedicine (Lond) 2012, 7:271-288.
3. Alberti M.O., Roth J.C., Ismail M., Tsuruta Y., Abraham E., Pereboeva L., et al. Derivation of a myeloid cell-binding adenovirus for gene therapy of inflammation. PLoS One 2012, 7:e37812.
4. Vigne E., Dedieu J.F., Brie A., Gillardeaux A., Briot D., Benihoud K., et al. Genetic manipulations of adenovirus type 5 fiber resulting in liver tropism attenuation. Gene Ther 2003, 10:153-162.
5. Liu Y., Koziol J., Deisseroth A., Borgstrom P. Methods for delivery of adenoviral vectors to tumor vasculature. Hum Gene Ther 2007, 18:151-160.
6. Yun C.O., Yoon A.R., Yoo J.Y., Kim H., Kim M., Ha T., et al. Coxsackie and adenovirus receptor binding ablation reduces adenovirus liver tropism and toxicity. Hum Gene Ther 2005, 16:248-261.
7. Dmitriev I., Krasnykh V., Miller C.R., Wang M., Kashentseva E., Mikheeva G., et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998, 72:9706-9713.
8. Wickham T.J., Tzeng E., Shears L.L., Roelvink P.W., Li Y., Lee G.M., et al. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol 1997, 71:8221-8229.
9. Bouri K., Feero W.G., Myerburg M.M., Wickham T.J., Kovesdi I., Hoffman E.P., et al. Polylysine modification of adenoviral fiber protein enhances muscle cell transduction. Hum Gene Ther 1999, 10:1633-1640.
10. Gonzalez R., Vereecque R., Wickham T.J., Facon T., Hetuin D., Kovesdi I., et al. Transduction of bone marrow cells by the AdZ.F(pK7) modified adenovirus demonstrates preferential gene transfer in myeloma cells. Hum Gene Ther 1999, 10:2709-2717.
11. Koivunen E., Wang B., Ruoslahti E. Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Biotechnology (N Y) 1995, 13:265-270.
12. Fromm J.R., Hileman R.E., Caldwell E.E., Weiler J.M., Linhardt R.J. Differences in the interaction of heparin with arginine and lysine and the importance of these basic amino acids in the binding of heparin to acidic fibroblast growth factor. Arch Biochem Biophys 1995, 323:279-287.
13. Zheng S., Ulasov I.V., Han Y., Tyler M.A., Zhu Z.B., Lesniak M.S. Fiber-knob modifications enhance adenoviral tropism and gene transfer in malignant glioma. J Gene Med 2007, 9:151-160.
14. Denby L., Work L.M., Seggern D.J., Wu E., McVey J.H., Nicklin S.A., et al. Development of renal-targeted vectors through combined in vivo phage display and capsid engineering of adenoviral fibers from serotype 19p. Mol Ther 2007, 15:1647-1654.
15. Myhre S., Henning P., Friedman M., Stahl S., Lindholm L., Magnusson M.K. Re-targeted adenovirus vectors with dual specificity; binding specificities conferred by two different Affibody molecules in the fiber. Gene Ther 2009, 16:252-261.
16. Macleod S.H., Elgadi M.M., Bossi G., Sankar U., Pisio A., Agopsowicz K., et al. HER3 targeting of adenovirus by fiber modification increases infection of breast cancer cells in vitro, but not following intratumoral injection in mice. Cancer Gene Ther 2012.
17. Poulin K.L., Lanthier R.M., Smith A.C., Christou C., Risco Quiroz M., Powell K.L., et al. Retargeting of adenovirus vectors through genetic fusion of a single-chain or single-domain antibody to capsid protein IX. J Virol 2010, 84:10074-10086.
18. Vellinga J., de Vrij J., Myhre S., Uil T., Martineau P., Lindholm L., et al. Efficient incorporation of a functional hyper-stable single-chain antibody fragment protein-IX fusion in the adenovirus capsid. Gene Ther 2007, 14:664-670.
19. Hedley S.J., Auf der Maur A., Hohn S., Escher D., Barberis A., Glasgow J.N., et al. An adenovirus vector with a chimeric fiber incorporating stabilized single chain antibody achieves targeted gene delivery. Gene Ther 2006, 13:88-94.
20. Worn A., Pluckthun A. Stability engineering of antibody single-chain Fv fragments. J Mol Biol 2001, 305:989-1010.
21. Ohage E.C., Wirtz P., Barnikow J., Steipe B. Intrabody construction and expression. II. A synthetic catalytic Fv fragment. J Mol Biol 1999, 291:1129-1134.
22. Tavladoraki P., Girotti A., Donini M., Arias F.J., Mancini C., Morea V., et al. A single-chain antibody fragment is functionally expressed in the cytoplasm of both Escherichia coli and transgenic plants. Eur J Biochem 1999, 262:617-624.
23. Glasgow J.N., Mikheeva G., Krasnykh V., Curiel D.T. A strategy for adenovirus vector targeting with a secreted single chain antibody. PLoS One 2009, 4:e8355.
24. Magnusson M.K., Hong S.S., Henning P., Boulanger P., Lindholm L. Genetic retargeting of adenovirus vectors: functionality of targeting ligands and their influence on virus viability. J Gene Med 2002, 4:356-370.
25. Cattaneo A., Biocca S. The selection of intracellular antibodies. Trends Biotechnol 1999, 17:115-121.
26. Koide A., Bailey C.W., Huang X., Koide S. The fibronectin type III domain as a scaffold for novel binding proteins. J Mol Biol 1998, 284:1141-1151.
27. Emanuel S.L., Engle L.J., Chao G., Zhu R.R., Cao C., Lin Z., et al. A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor. MAbs 2011, 3:38-48.
28. Lipovsek D. Adnectins: engineered target-binding protein therapeutics. Protein Eng Des Sel 2011, 24:3-9.
29. Getmanova E.V., Chen Y., Bloom L., Gokemeijer J., Shamah S., Warikoo V., et al. Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitro. Chem Biol 2006, 13:549-556.
30. Koide A., Gilbreth R.N., Esaki K., Tereshko V., Koide S. High-affinity single-domain binding proteins with a binary-code interface. Proc Natl Acad Sci U S A 2007, 104:6632-6637.
31. Batori V., Koide A., Koide S. Exploring the potential of the monobody scaffold: effects of loop elongation on the stability of a fibronectin type III domain. Protein Eng 2002, 15:1015-1020.
32. Krasnykh V., Belousova N., Korokhov N., Mikheeva G., Curiel D.T. Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin. J Virol 2001, 75:4176-4183.
33. Pereboeva L., Komarova S., Mahasreshti P.J., Curiel D.T. Fiber-mosaic adenovirus as a novel approach to design genetically modified adenoviral vectors. Virus Res 2004, 105:35-46.
34. Sawano A., Takahashi T., Yamaguchi S., Aonuma M., Shibuya M. Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor. Cell Growth Differ 1996, 7:213-221.
35. Mizuguchi H., Koizumi N., Hosono T., Utoguchi N., Watanabe Y., Kay M.A., et al. A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob. Gene Ther 2001, 8:730-735.
36. Koizumi N., Mizuguchi H., Utoguchi N., Watanabe Y., Hayakawa T. Generation of fiber-modified adenovirus vectors containing heterologous peptides in both the HI loop and C terminus of the fiber knob. J Gene Med 2003, 5:267-276.
37. Mizuguchi H., Hayakawa T. Characteristics of adenovirus-mediated tetracycline-controllable expression system. Biochim Biophys Acta 2001, 1568:21-29.
38. Koizumi N., Mizuguchi H., Sakurai F., Yamaguchi T., Watanabe Y., Hayakawa T. Reduction of natural adenovirus tropism to mouse liver by fiber-shaft exchange in combination with both CAR- and alphav integrin-binding ablation. J Virol 2003, 77:13062-13072.
39. Maizel J.V., White D.O., Scharff M.D. The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology 1968, 36:115-125.
40. Matsui H., Sakurai F., Kurachi S., Tashiro K., Sugio K., Kawabata K., et al. Development of fiber-substituted adenovirus vectors containing foreign peptides in the adenovirus serotype 35 fiber knob. Gene Ther 2009, 16:1050-1057.
41. Weihua Z., Tsan R., Huang W.C., Wu Q., Chiu C.H., Fidler I.J., et al. Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 2008, 13:385-393.
42. Manke I.A., Nguyen A., Lim D., Stewart M.Q., Elia A.E., Yaffe M.B. MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G2/M transition and S phase progression in response to UV irradiation. Mol Cell 2005, 17:37-48.
43. Murakami S., Sakurai F., Kawabata K., Okada N., Fujita T., Yamamoto A., et al. Interaction of penton base Arg-Gly-Asp motifs with integrins is crucial for adenovirus serotype 35 vector transduction in human hematopoietic cells. Gene Ther 2007, 14:1525-1533.
44. Humphrey P.A., Wong A.J., Vogelstein B., Friedman H.S., Werner M.H., Bigner D.D., et al. Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. Cancer Res 1988, 48:2231-2238.
45. Modjtahedi H., Eccles S., Box G., Styles J., Dean C. Immunotherapy of human tumour xenografts overexpressing the EGF receptor with rat antibodies that block growth factor-receptor interaction. Br J Cancer 1993, 67:254-261.
46. Lu D., Jimenez X., Zhang H., Bohlen P., Witte L., Zhu Z. Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy. Int J Cancer 2002, 97:393-399.
47. Ryden L., Jirstrom K., Bendahl P.O., Ferno M., Nordenskjold B., Stal O., et al. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer. J Clin Oncol 2005, 23:4695-4704.
48. Jones P.T., Dear P.H., Foote J., Neuberger M.S., Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986, 321:522-525.
49. Proba K., Worn A., Honegger A., Pluckthun A. Antibody scFv fragments without disulfide bonds made by molecular evolution. J Mol Biol 1998, 275:245-253.
50. Worn A., Pluckthun A. An intrinsically stable antibody scFv fragment can tolerate the loss of both disulfide bonds and fold correctly. FEBS Lett 1998, 427:357-361.
51. Martineau P., Jones P., Winter G. Expression of an antibody fragment at high levels in the bacterial cytoplasm. J Mol Biol 1998, 280:117-127.
52. Cortez-Retamozo V., Lauwereys M., Hassanzadeh Gh G., Gobert M., Conrath K., Muyldermans S., et al. Efficient tumor targeting by single-domain antibody fragments of camels. Int J Cancer 2002, 98:456-462.
53. Tolcher A.W., Sweeney C.J., Papadopoulos K., Patnaik A., Chiorean E.G., Mita A.C., et al. Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin. Clin Cancer Res 2011, 17:363-371.
54. Meulenbroek R.A., Sargent K.L., Lunde J., Jasmin B.J., Parks R.J. Use of adenovirus protein IX (pIX) to display large polypeptides on the virion-generation of fluorescent virus through the incorporation of pIX-GFP. Mol Ther 2004, 9:617-624.
55. de Vrij J., Uil T.G., van den Hengel S.K., Cramer S.J., Koppers-Lalic D., Verweij M.C., et al. Adenovirus targeting to HLA-A1/MAGE-A1-positive tumor cells by fusing a single-chain T-cell receptor with minor capsid protein IX. Gene Ther 2008, 15:978-989.
56. Campos S.K., Barry M.A. Comparison of adenovirus fiber, protein IX, and hexon capsomeres as scaffolds for vector purification and cell targeting. Virology 2006, 349:453-462.
57. Kurachi S., Koizumi N., Sakurai F., Kawabata K., Sakurai H., Nakagawa S., et al. Characterization of capsid-modified adenovirus vectors containing heterologous peptides in the fiber knob, protein IX, or hexon. Gene Ther 2007, 14:266-274.
58. Ghosh-Choudhury G., Haj-Ahmad Y., Graham F.L. Protein IX, a minor component of the human adenovirus capsid, is essential for the packaging of full length genomes. EMBO J 1987, 6:1733-1739.
59. Rosa-Calatrava M., Grave L., Puvion-Dutilleul F., Chatton B., Kedinger C. Functional analysis of adenovirus protein IX identifies domains involved in capsid stability, transcriptional activity, and nuclear reorganization. J Virol 2001, 75:7131-7141.
60. Vellinga J., Rabelink M.J., Cramer S.J., van den Wollenberg D.J., Van der Meulen H., Leppard K.N., et al. Spacers increase the accessibility of peptide ligands linked to the carboxyl terminus of adenovirus minor capsid protein IX. J Virol 2004, 78:3470-3479.
61. Kirby I., Davison E., Beavil A.J., Soh C.P., Wickham T.J., Roelvink P.W., et al. Identification of contact residues and definition of the CAR-binding site of adenovirus type 5 fiber protein. J Virol 2000, 74:2804-2813.
62. Smith T.A., Idamakanti N., Rollence M.L., Marshall-Neff J., Kim J., Mulgrew K., et al. Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice. Hum Gene Ther 2003, 14:777-787.